



MRN: _____

Phone: 1-800-809-1265 Fax: 1-866-872-8920

DOB: _____

Guidelines for Prescribing Tysabri® (natalizumab) for Multiple Sclerosis

(Required documentation with all initial referrals)

Patient Name: _____

Referral Date: _____

____ Tysabri® (natalizumab) is restricted to credentialed prescribers and patients enrolled in the TOUCH® Prescribing Program. Contact TOUCH® Prescribing Program at 1-800-456-2255 for details and enrollment. TOUCH® Authorization form must be received prior to scheduling.

____ Include signed and completed **Plan of Treatment**. (MD must complete sections 1-6)
(Infusion order forms & Standard Adverse Reactions orders are available at www.palmettoinfusion.com under Agency/MD tab)

____ Include patient demographic information and insurance information. (Copy of insurance cards if available)

____ **Supporting clinical MD notes to include any past tried and/or failed therapies, intolerance, outcomes or contraindications to conventional therapy. Include any lab results and/or tests to support diagnosis.**

- TYSABRI® (natalizumab) is an integrin receptor antagonist indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis. TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML).

____ Include the following:
Past tried and/or failed therapies: _____
Last known therapy: _____ and last date received: _____.
MD must specify wash-out period prior to starting Tysabri® as specified of _____ weeks.

____ Other as requested: _____

Pre-Screening:

____ **anti-JCV antibodies test results within last 6 months.** (Patients who are anti-JCV antibody positive, will require documentation from referring MD that risks and benefits have been discussed)

**** Warnings/Precautions:** TYSABRI® increases the risk of **progressive multifocal leukoencephalopathy (PML)**: an opportunistic viral infection of the brain that usually leads to death or severe disability • Risk factors for the development of PML include duration of therapy, prior use of immunosuppressants, and presence of anti-JCV antibodies. • Healthcare professionals should monitor patients on TYSABRI® for any new sign or symptom that may be suggestive of PML. TYSABRI® dosing should be withheld immediately at the first sign or symptom suggestive of PML. • **Herpes encephalitis and meningitis:** Life-threatening and fatal cases have occurred, discontinue TYSABRI® if this occurs • **Hepatotoxicity:** Significant liver injury, including liver failure requiring transplant, has occurred. Discontinue TYSABRI® in patients with evidence of liver injury. • **Immunosuppression/Infections:** TYSABRI® may increase the risk for certain infections including: pneumonias, urinary tract infections (including serious cases), gastroenteritis, vaginal infections, tooth infections, tonsillitis, and herpes infections. • **Hypersensitivity reactions:** Serious hypersensitivity reactions (e.g., anaphylaxis) have occurred. **Permanently discontinue TYSABRI® if such a reaction occurs. •Pregnancy Category C.** See full prescribing information.

Palmetto Infusion Services will complete insurance verification and submit all required clinical documentation to the patient’s insurance company for eligibility. Our office will notify you if any further information is required. We will review financial responsibility with the patient and refer them to any available Co-pay assistance as required. Thank you for the referral.

Please fax all information to 1-866-872-8920 or call 1-800-809-1265 for assistance.